| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.13.2.170 |
| P698 | PubMed publication ID | 8427854 |
| P2093 | author name string | J Shepherd | |
| G M Lindsay | |||
| B A Griffin | |||
| A Gaw | |||
| C J Packard | |||
| A R Lorimer | |||
| M J Caslake | |||
| B D Vallance | |||
| E F Murray | |||
| P433 | issue | 2 | |
| P921 | main subject | simvastatin | Q670131 |
| P304 | page(s) | 170-189 | |
| P577 | publication date | 1993-02-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Effects of simvastatin on apoB metabolism and LDL subfraction distribution | |
| P478 | volume | 13 |
| Q36455892 | Apolipoproteins AI and B as therapeutic targets |
| Q51565510 | Association between low-density lipoprotein composition and its metabolism in non-insulin-dependent diabetes mellitus. |
| Q41445253 | Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors |
| Q72546747 | Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability |
| Q61862747 | Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects |
| Q72783966 | Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia |
| Q44346408 | Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. |
| Q73712789 | Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia |
| Q33738872 | Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study |
| Q43754356 | Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. |
| Q71858808 | Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia |
| Q32076763 | Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia |
| Q77052068 | Evidence based approach for the management of mixed hyperlipidaemia |
| Q51590571 | Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance |
| Q33829121 | Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm |
| Q46411630 | Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin |
| Q44064898 | Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates |
| Q42166736 | Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia. |
| Q40964792 | Low-density lipoprotein heterogeneity |
| Q77714389 | Metabolic modes of action of the statins in the hyperlipoproteinemias |
| Q34478635 | Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? |
| Q24626884 | Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk |
| Q49554117 | Pharmacological Intervention to Modulate HDL: What Do We Target? |
| Q77366640 | Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q46607350 | Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study |
| Q72877429 | Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment |
| Q71814893 | Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications |
| Q40923088 | Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia |
| Q73229434 | Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia |
| Q34090712 | Statins do not decrease small, dense low-density lipoprotein |
| Q33876942 | Statins: effective antiatherosclerotic therapy |
| Q34687736 | Statins: mechanism of action and effects. |
| Q33944807 | The role of small, dense low density lipoprotein (LDL): a new look |
| Q40964813 | The role of stable isotopes in the investigation of plasma lipoprotein metabolism |
Search more.